What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes

Diabetes Care

Volumn 26, Issue 2, 2003, Pages 536-538

  Palmer, Jerry P ^a,b   Hirsch, Irl B ^b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; HLA DQ ANTIGEN; HLA DR2 ANTIGEN;

AUTOIMMUNE DISEASE; DIABETES MELLITUS; EDITORIAL; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MATURITY ONSET DIABETES MELLITUS; NOMENCLATURE; PANCREAS ISLET BETA CELL; PATIENT CARE; SEMANTICS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ONSET AGE;

AGE OF ONSET; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; TERMINOLOGY;

EID: 0042092541     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2.536     Document Type: Editorial

References (14)

1. Irvine WJ, Gray RS, McCallum CJ, Duncan LJP: Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycemic agents. Lancet 1:1025-1027, 1977
2. Zimmet PZ: The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diabetes Care 18:1050-1064, 1994
3. Juneja R, Palmer JP: Type 11/2 diabetes: myth or reality. Autoimmunity 29:65-83, 1999
4. Hosszúfalusi N, Vatay A, Rajczy K, Prohászka Z, Pozsonyi É, Horváth L, Grosz A, Gerõ L, Madácsy L, Romics L, Karádi I, Füst G, Pánczél P: Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452-457, 2003
5. Tuomi T, Carlsson Å, Li H, Isomaa B, Miettinen A, Nilsson A, Nissén M, Ehrnström B, Forsén B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen M, Groop L: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157, 1999
6. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G: β-cell function in relation to islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16:902-910, 1993
7. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. Ann Intern Med 128:517-523, 1998
8. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP: Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 11/2 diabetes in patients presenting with type 2 diabetes. Metabolism 50:1008-1013, 2001
9. Seissler J, de Sonnaville JJJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA: Immunological heterogeneity in type 1 diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 41:891-897, 1998
10. Hampe CS, Kockum I, Landin-Olsson M, Torn C, Ortqvist E, Persson B, Rolandsson O, Palmer JP, Lemmark A: GAD65 antibody epitope patterns of type 1.5 diabetic patients are consistent with slow-onset autoimmune diabetes. Diabetes Care 25:1481-1482, 2002
11. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP: Cellular immune responses to human islet protein in antibody-positive type 2 diabetic patients. Diabetes 48:983-988, 1999
12. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JP: Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 166:5265-5270, 2001
13. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR: B-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (Dia-Pep277): a randomized, double blind, phase II trial. Lancet 358:1749-1753, 2001
14. Carlsson A, Sundkvist G, Groop L, Tuomi T: Insulin and glucagon secretion in patients with slowly progressive autoimmune diabetes (LADA). J Clin Endocrinol Metab 85:76-80, 2000